US 11,866,413 B2
Composition of 5-fluorouracil and refining method therefor
Xiaolin Chen, Shanghai (CN); Pengfei Gao, Shanghai (CN); Yike Yang, Shanghai (CN); Yi Liang, Shanghai (CN); and Yafeng Zhan, Shanghai (CN)
Assigned to SHANGHAI XUDONG HAIPU PHARMACEUTICAL CO., LTD, Shanghai (CN)
Appl. No. 17/629,777
Filed by SHANGHAI XUDONG HAIPU PHARMACEUTICAL CO., LTD, Shanghai (CN)
PCT Filed Jan. 10, 2020, PCT No. PCT/CN2020/071350
§ 371(c)(1), (2) Date Jan. 24, 2022,
PCT Pub. No. WO2021/022788, PCT Pub. Date Feb. 11, 2021.
Claims priority of application No. 201910716013.1 (CN), filed on Aug. 5, 2019.
Prior Publication US 2022/0348548 A1, Nov. 3, 2022
Int. Cl. C07D 239/553 (2006.01)
CPC C07D 239/553 (2013.01) 13 Claims
 
1. A 5-fluorouracil raw material or active pharmaceutical ingredient, comprising 5-fluorouracil with a weight percentage of 99.9% or more and impurities with a weight percentage of 0.05% or less, and the impurities are selected from 5-methoxyuracil, and dihydropyrimidine-2,4,5(3H)-trione;
wherein the structure of the 5-methoxyuracil is

OG Complex Work Unit Chemistry
 and
the structure of the dihydropyrimidine-2,4,5(3H)-trione is

OG Complex Work Unit Chemistry